{
  "id": "clinical#screening_cues_4a134f53",
  "content": "Volatile inhalants 6C4B.5 6C4B.6 6C4B.70 6C4B.71 N/A N/A 6D72.13 6D84.2\n6C4G.0 Episode of harmful use of unknown or unspecified psychoactive substances\nMDMA or related drugs, 6C4C.5 6C4C.6 6C4C.70 6C4C.71 N/A N/A N/A N/A\nincluding MDA\nDissociative drugs, 6C4D.4 6C4D.5 6C4D.60 6C4D.61 N/A N/A N/A N/A\nincluding ketamine\nand PCP\nEssential (required) features\nOther specified 6C4E.5 6C4E.6 6C4E.70 6C4E.71 6C4E.72 6C4E.73 6D72.12 6D84.Y\nMultiple specified 6C4F.5 6C4F.6 6C4F.70 6C4F.71 6C4F.72 6C4F.73 N/A N/A\nUnknown or unspecified 6C4G.5 6C4G.6 6C4G.70 6C4G.71 6C4G.72 6C4G.73 N/A N/A\nNon-psychoactive N/A N/A N/A N/A N/A N/A N/A N/A • An episode of use of a psychoactive substance that has caused clinically significant\ndamage to a person’s physical health (e.g. bloodborne infection from intravenous self-\na H = with hallucinations, D = with delusions, M = with mixed psychotic symptoms\nadministration) or mental health (e.g. substance-induced mood disorder), or has resulted\nin behaviour leading to harm to the health of others, is required for diagnosis.\n• Harm to the health of the individual occurs due to one or more of the following: behaviour\nrelated to intoxication (see Table 6.15, p. 475); direct or secondary toxic effects on body\norgans and systems; or a harmful route of administration.\n• Harm to the health of others includes any form of physical harm, including trauma, or",
  "metadata": {
    "source": "WHO ICD-11",
    "url": "https://icd.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues Volatile inhalants 6C4B.5 6C4B.6 6C4B.70 6C4B.71 N/A N/A 6D72.13 6D84.2\n6C4G.0 Episode of harmful use of unknown or unspecified psychoactive substances\nMDMA or related drugs, 6C4C.5 6C4C.6 6C4C.70 6C4C.71 N/A N/A N/A N/A\nincluding MDA\nDissociative drugs, 6C4D.4 6C4D.5 6C4D.60 6C4D.61 N/A N/A N/A N/A\nincluding ketamine\nand PCP\nEssential (required) features\nOther specified 6C4E.5 6C4E.6 6C4E.70 6C4E.71 6C4E.72 6C4E.73 6D72.12 6D84.Y\nMultiple specified 6C4F.5 6C4F.6 6C4F.70 6C4F.71 6C4F.72 6C4F.73 N/A N/A\nUnknown or unspecified 6C4G.5 6C4G.6 6C4G.70 6C4G.71 6C4G.72 6C4G.73 N/A N/A\nNon-psychoactive N/A N/A N/A N/A N/A N/A N/A N/A • An episode of use of a psychoactive substance that has caused clinically significant\ndamage to a person’s physical health (e.g. bloodborne infection from intravenous self-\na H = with hallucinations, D = with delusions, M = with mixed psychotic symptoms\nadministration) or mental health (e.g. substance-induced mood disorder), or has resulted\nin behaviour leading to harm to the health of others, is required for diagnosis.\n• Harm to the health of the individual occurs due to one or more of the following: behaviour\nrelated to intoxication (see Table 6.15, p. 475); direct or secondary toxic effects on body\norgans and systems; or a harmful route of administration.\n• Harm to the health of others includes any form of physical harm, including trauma, or Volatile inhalants 6c4b.5 6c4b.6 6c4b.70 6c4b.71 n/a n/a 6d72.13 6d84.2\n6c4g.0 episode of harmful use of unknown or unspecified psychoactive substances\nmdma or related drugs, 6c4c.5 6c4c.6 6c4c.70 6c4c.71 n/a n/a n/a n/a..."
}